Vilon

What it is

Vilon belongs to the cytogens, the synthetic short peptides of the Khavinson school. It consists of lysine and glutamic acid and is thus the simplest molecule in the entire series. In the Russian specialist literature it is listed as a thymomimetic, that is, a substance intended to mimic effects of the thymus, and as a synthetic counterpart to the thymus extract Thymalin, which has been described as a medicine since the early 1980s.

A 2021 review by the group reports that KE does in fact occur in Thymalin: using mass spectrometry, the dipeptide KE and the tripeptide EDP, which is sold as Crystagen, were found in the extract. Vilon is therefore not an artificial product but a component of a well-known organ preparation.

What is striking is how frequently the KE motif occurs in the body. According to the same review, proteins of the cell nucleus contain particularly many KE segments. The group suspects that KE fragments released during the breakdown of such proteins themselves bind to DNA and regulate genes. This is a hypothesis, not a measured chain.

How it is supposed to work

Vilon is supposed to rejuvenate the aging immune system, whose central organ, the thymus, shrinks with age. In organ cultures of the pineal gland, Vilon stimulated precursor cells to develop into T helper cells, cytotoxic T cells and B cells. In human monocytes, tested by an Italian working group with Khavinson as co-author, Vilon and four other peptides dampened the inflammatory messengers TNF and IL-6 after a bacterial stimulus.

The second track is the genome. In lymphocytes of old people, Vilon loosened condensed chromatin in the test tube and activated ribosomal genes. In human mesenchymal stem cells, KE increased the gene and protein of SIRT1, an enzyme of the stress defense, 6-fold and 8.2-fold, and lowered the DNA repair enzymes PARP1 and PARP2 during cellular aging.

One detail from the chromatin work is interesting: unlike Epitalon and Livagen, Vilon did not loosen the tightly packed structural chromatin around the centromeres. Each peptide therefore seems to address specific regions of the genome. In rats, Vilon also increased resilience to emotional stress and slowed stress-related changes in the adrenal glands and thymus.

Lifespan and cancer in animal models

The 2000 lifespan study is the most prominent finding on Vilon. Female mice that regularly received Vilon from the 6th month of life were more active and had more stamina, lived longer and developed spontaneous tumors less often. The authors found no adverse effects of long-term administration. A 2010 review gives an increase in mean lifespan of 20 to 40 percent for long-term administration of various peptide preparations in rodents; a separate figure for Vilon is not given there.

Vilon also showed an effect against chemically induced tumors. Bladder tumors developed in 56 percent of treated rats compared with 75.5 percent of controls. After the intestinal carcinogen dimethylhydrazine, 14.3 percent of treated mice developed tumors, compared with 60 percent without Vilon.

What the studies show

Coagulation in type 1 diabetes (2006)

Kuznik and colleagues found accelerated coagulation, fewer natural anticoagulants and slowed fibrinolysis in unstable type 1 diabetes. Under Vilon, this picture was markedly reduced or disappeared, less so in older, seriously ill patients. The paper is indexed as randomized, but the abstract gives no participant number, and the full text is in Russian.

Insulin requirement and immune status (2007)

In a follow-up paper in older diabetes patients, antithrombin III and protein C rose under Vilon as add-on therapy, fibrinolysis increased, and in most cases the required insulin dose fell. Some immune parameters normalized. Here, too, the abstract lacks the participant number.

Lifespan in mice (2000)

Khavinson and colleagues gave female CBA mice Vilon under the skin from the 6th month of life. The animals were more active, lived longer and had spontaneous tumors less often; long-term administration proceeded without recognizable harm. The abstract gives no percentage for the life extension.

Breast cancer in transgenic mice (2002)

Alimova and colleagues compared Vilon and Epitalon in mice carrying the oncogene HER2/neu. Epitalon inhibited cancer development, Vilon did not: two or more tumors per animal were found in 75 percent of controls, 95 percent of Vilon animals and 56 percent of Epitalon animals. Lung metastases were 2.6 times more frequent under Vilon than under Epitalon.

Where the data stop

The clinical papers can be assessed only to a limited extent. They are published in Russian, the accessible abstracts give no participant numbers, and their endpoints are lab values such as coagulation markers or the insulin dose. The cancer study itself speaks of preliminary results. There is no independent replication outside the developers’ circle, and no Vilon study can be found in ClinicalTrials.gov.

The tumor data are not consistent. Fewer chemically induced tumors are set against an experiment in which Vilon animals had multiple tumors more often than controls. A review by the group instead mentions that KE halves the expression of HER-2/neu in transgenic mice; the unfavorable finding is not discussed there. Some advertising claims also go beyond the data: an effect on the retina could not be found for Vilon, and the strengthening of T helper cells has been shown in cell cultures, not in older people.

Status, approval and legal

Vilon is not an approved medicine in Germany or the EU. As a food supplement it would require authorization under the Novel Food Regulation (EU) 2015/2283, which does not exist. It is traded as a capsule product or research peptide via online retailers. It is not named on the World Anti-Doping Agency’s Prohibited List, but as a non-approved substance it falls under group S0 and is banned in sport at all times.

Safety

Systematic safety data in humans do not exist; the clinical abstracts report no side effects, but also describe no safety evaluation. Lifelong administration in mice proceeded without recognizable harm. Two findings deserve attention: Vilon alters coagulation and fibrinolysis, but interactions with anticoagulants have never been studied, and it lowered the insulin requirement in diabetes, which in insulin therapy without medical supervision could carry a risk of hypoglycemia. In autoimmune diseases, immune activation has not been studied. After cancer, especially HER2-positive breast cancer, the unfavorable mouse finding argues for caution. There are no data for pregnancy and breastfeeding.

Sources

• Khavinson et al., Bull Exp Biol Med 2000 – Vilon, biological age and lifespan in mice
• Kuznik et al., Adv Gerontol 2006 – Vilon and coagulation in type 1 diabetes
• Kuznik et al., Adv Gerontol 2007 – Vilon, immune status and hemostasis in diabetes
• Iaskevich et al., Adv Gerontol 2005 – peptide bioregulator in older cancer patients
• Alimova et al., Vopr Onkol 2002 – Epitalon and Vilon in HER2/neu mice
• Pliss et al., Bull Exp Biol Med 2001 – Vilon and chemically induced bladder tumors
• Lezhava et al., Biogerontology 2004 – Vilon reactivates chromatin in lymphocytes of old people
• Khavinson et al., Adv Gerontol 2023 – KE, SIRT1, PARP1 and PARP2 in aging stem cells
• Avolio et al., Int J Mol Sci 2022 – Khavinson peptides in human monocytes
• Khavinson et al., Biol Bull Rev 2021 – Thymalin and its short peptides KE, EW and EDP (review)